≥98%(HPLC) , 1020149-73-8
Synonym(s):
N-(4-(2-Amino-6-methylpyrimidin-4-ylamino)phenyl)-4-(quinolin-4-ylamino) benzamide
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB1293.00 | In Stock |
|
| 25mg | RMB5174.79 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >280℃ |
| Density | 1.387±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | Soluble in DMSO (up to 35 mg/ml) |
| pka | 13.31±0.70(Predicted) |
| form | powder |
| color | white to light brown |
| Stability: | Stable for 2 years as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Description and Uses
SGI-1027 (1020149-73-8) is a potent and selective inhibitor of DNA methyl transferase inhibiting DNMT1, DNMT3A and DNMT3B with comparable potency (IC50=12.5, 8.0 and 7.5 mM respectively).1? Treatment of various cancer cell lines with SGI-1027 results in selective degradation of DNMT1 (MG-132 sensitive) with minimal effect on DNMT3A and 3B at 2.5-5 mM.1 Prolonged treatment of RKO cells resulted in reexpression of silenced tumor suppressor genes.1 Synergizes with doxorubicin at growth inhibition in neuroblastoma cell lines.2 Disrupts the MKK3-MYC complex in cells and inhibits MYC transcriptional activity in colon and breast cancer cells.3
SGI-1027 is a quinoline derivative and a potent inhibitor of DNA methyltransferase (DNMT). SGI-1027 can be used as a potential therapeutic agent for the treatment of cancer and other diseases and also as a research tool to investigate the role of DNMTs in epigenetic events.
